** Shares of drug developer Aldeyra Therapeutics rise 10.4% to $3.60 premarket
** Co says its experimental therapy to treat dry eye disease met the main goal of a late-stage study
** Dry eye disease affects the layers of tears that cover the cornea causing symptoms like burning, itching and blurred vision
** Co says the therapy reproxalap was statistically superior in reducing the symptom of ocular discomfort in patients
** Trial was designed to satisfy the U.S. FDA's marketing application resubmission requirement - co
** No safety signals were observed in the clinical trial, and reproxalap was well tolerated- ALDX
** The FDA last year rejected the therapy as it did not demonstrate efficacy in treating symptoms of the disease
** Up to last close, stock down 7.1% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Comments